ClinicalTrials.gg
Not yet recruitingNCT06953128GENERAUpdated Jun 26, 2025

General Versus Regional Anesthesia in Peripheral Arterial Surgery

An interventional study of Spinal Anesthesia and General Anesthesia in Postoperative Complications and Cardiovascular Diseases, sponsored by Hospital de Clinicas de Porto Alegre. Not yet recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by Hospital de Clinicas de Porto Alegre · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
594
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Postoperative Complications with a site in Brazil — 8 open to participants now, 8 under way, none of them phase 3. Postoperative Complications · Brazil.

Planned enrollment
4th of 25
594 · median 118
Started
2025
the only one that year
No phase
17 of 36
3 open now
Registered
32nd of 36
by date
Lead sponsor
4 of 36
Hospital de Clinicas de Porto Alegre

Among the 36 studies in Postoperative Complications with a site in Brazil, this one is the 4th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2025, is one of 17 with no phase, and was the 32nd registered.

Postoperative Complications

1,343 studies on the registry are indexed under Postoperative Complications; 314 are open to participants now.

Browse Postoperative Complications studies →

Open to participants now

8 of the 36 studies in Postoperative Complications with a site in Brazil are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 200 Postoperative Complications studies recruiting now, 126 (63%) set no upper age limit and 31 (16%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Postoperative Complications with a site in Brazil, or all of them as a file.
02

Study summary

This multicenter, prospective, randomized clinical trial aims to compare the effects of spinal (neuraxial) anesthesia with spontaneous ventilation versus general anesthesia with mechanical ventilation on the incidence of postoperative pulmonary complications in adult patients undergoing elective lower limb revascularization surgery. A total of 594 patients with symptomatic peripheral arterial disease will be randomly assigned to receive either spinal anesthesia with sedation or general anesthesia with mechanical ventilation. The primary outcome is the incidence of postoperative pulmonary complications within 30 days or until hospital discharge, including pneumonia, respiratory failure, pleural effusion, atelectasis, and other defined respiratory events. Secondary outcomes include cardiovascular events, hemodynamic instability, renal injury, delirium, extrapulmonary complications, adverse events in the operated limb, ICU and hospital length of stay, and mortality. The study will be conducted at Hospital de Clínicas de Porto Alegre, Hospital Nossa Senhora da Conceição, and other participating Brazilian centers, with an expected start date in July 2025 and completion in December 2029.

Read the detailed description

This is a prospective, randomized, multicenter clinical trial designed to evaluate the impact of the anesthetic technique-general anesthesia with mechanical ventilation versus spinal (neuraxial) anesthesia with spontaneous ventilation-on the incidence of postoperative pulmonary complications in patients undergoing elective peripheral arterial revascularization surgery. The study population will include 594 adult patients (ASA II-IV) with symptomatic critical limb ischemia, scheduled for elective lower limb revascularization at tertiary hospitals in Brazil. Patients will be randomized into two groups: Group 1 will receive spinal anesthesia with intravenous sedation and supplemental nasal oxygen; Group 2 will receive general anesthesia with controlled mechanical ventilation using lung-protective strategies (tidal volume 6-8 mL/kg and PEEP 5 cmH₂O).

The primary outcome is the incidence of postoperative pulmonary complications within 30 days after surgery or until hospital discharge. These include pneumonia, respiratory failure, pleural effusion, atelectasis, pneumothorax, aspiration pneumonitis, bronchospasm, ARDS, pulmonary embolism, and exacerbation of preexisting respiratory disease, defined according to internationally recognized criteria.

Secondary outcomes include:

  1. major cardiovascular complications (nonfatal myocardial infarction, acute coronary syndrome, cardiogenic shock);
  2. hemodynamic complications (prolonged hypotension or distributive shock requiring vasopressors);
  3. other extrapulmonary complications such as acute kidney injury, stroke, delirium, sepsis, surgical limb complications (e.g., graft thrombosis, amputation), and thromboembolic events (e.g., DVT, PE);
  4. ICU and hospital length of stay, PACU time, and 30-day or in-hospital mortality.

Data collection will include perioperative gasometric evaluation, detailed intraoperative hemodynamic and ventilatory monitoring, analgesia and antiemetic usage, and adverse events tracking through predefined time points (intraoperative, immediate postoperative, and up to 30 days after surgery). Sample size calculation is based on detecting a reduction in pulmonary complications from 25% in the general anesthesia group to 15% in the spinal anesthesia group, with a power of 80% and a two-tailed alpha of 0.05. Randomization will be performed using computer-generated block sequences, and outcome assessors and statisticians will be blinded. The statistical analysis will follow the intention-to-treat principle and include regression modeling to control for potential confounders such as comorbidities and operative duration.

The study will begin in July 2025 and is expected to be completed by December 2029. Results will be published in peer-reviewed journals and used to inform perioperative management strategies in vascular surgery.

03

Conditions studied

  • Postoperative Complications
  • Cardiovascular Diseases

Keywords

  • Postoperative Pulmonary Complications
  • Peripheral Arterial Disease
  • Spinal Anesthesia
  • General Anesthesia
  • Vascular Surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥18 years
  • II to IV
  • Scheduled for elective peripheral arterial revascularization of the lower limbs
  • Diagnosis of symptomatic peripheral arterial disease with critical limb ischemia
  • Able and willing to provide

Exclusion criteria

Exclusion Criteria:

  • (BMI) > 40 kg/m²
  • Emergency vascular surgery
  • History of lung resection surgery
  • Persistent hemodynamic instability preoperatively
  • History of bronchial asthma or chronic therapy
  • History of neuromuscular disorders
  • Current use of anticoagulants or antiplatelet agents contraindicating spinal anesthesia
  • to spinal anesthesia (e.g., patient refusal, infection at puncture site, increased intracranial pressure, inability to cooperate due to agitation or cognitive impairment)
  • Acute vascular obstruction or other vascular complications not consistent with elective revascularization
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
594 participants (estimated)

Study arms

  • Experimental
    Spinal Anesthesia

    Patients in this group will receive spinal (neuraxial) anesthesia with isobaric bupivacaine (15-20 mg) and intrathecal morphine (100 μg), with optional clonidine as an adjuvant. Sedation may be provided with intravenous midazolam, fentanyl, and/or propofol, as per anesthesiologist discretion. Supplemental oxygen will be administered via nasal cannula. Patients will breathe spontaneously and will not be mechanically ventilated.

    Procedure: Spinal Anesthesia

  • Active comparator
    General Anesthesia

    Patients in this group will receive general anesthesia with intravenous induction (propofol or etomidate), opioids (remifentanil), and neuromuscular blockade (rocuronium), followed by endotracheal intubation and mechanical ventilation using a protective strategy (tidal volume 6-8 mL/kg predicted body weight and PEEP 5 cmH₂O). Anesthesia maintenance will include inhaled sevoflurane and continuous opioid infusion.

    Procedure: General Anesthesia

Interventions

  • ProcedureSpinal Anesthesia

    Participants will receive subarachnoid (spinal) anesthesia with 15-20 mg of isobaric bupivacaine 0.5% and 100 μg of intrathecal morphine. Clonidine (1 μg/kg) may be added at the discretion of the anesthesiologist. Sedation will be achieved with intravenous midazolam (up to 5 mg), fentanyl (up to 100 μg), and/or target-controlled infusion of propofol. Patients will remain spontaneously breathing throughout the procedure and receive supplemental oxygen via nasal cannula.

  • ProcedureGeneral Anesthesia

    Participants will undergo general anesthesia induced with intravenous propofol (1.5-2.5 mg/kg) or etomidate (0.2-0.3 mg/kg), remifentanil (0.2-0.4 μg/kg/min), and rocuronium (0.6 mg/kg), followed by endotracheal intubation and controlled mechanical ventilation. Maintenance will include continuous remifentanil infusion and inhaled sevoflurane. Ventilation parameters will follow a protective strategy (tidal volume 6-8 mL/kg predicted body weight and PEEP of 5 cmH₂O).

06

What researchers measure

Primary outcomes

  1. Incidence of Postoperative Pulmonary Complications

    Composite incidence of pulmonary complications occurring within 30 days after surgery or until hospital discharge. Events include: pneumonia, respiratory failure, pleural effusion, atelectasis, bronchospasm, aspiration pneumonitis, pneumothorax, pulmonary embolism, exacerbation of preexisting pulmonary disease, tracheobronchitis, and acute respiratory distress syndrome (ARDS), defined according to CDC and Berlin criteria.

    Time frame: Up to 30 days after surgery.

Secondary outcomes

  1. Incidence of Major Cardiovascular Complications

    Composite outcome including non-fatal myocardial infarction, acute coronary syndrome, and cardiogenic shock occurring in the perioperative period, defined by standard clinical and laboratory criteria.

    Time frame: Up to 30 days after surgery.

  2. Incidence of Hemodynamic Complications

    Incidence of distributive shock or persistent hypotension requiring vasopressor support during the perioperative period.

    Time frame: Up to 24 hours after surgery.

  3. Incidence of Extrapulmonary Complications

    Includes sepsis, acute kidney injury, delirium, stroke, venous thromboembolism, and surgical limb events (e.g., vascular graft thrombosis, ischemia, amputation), defined according to standardized criteria.

    Time frame: Up to 30 days after surgery.

  4. Length of Stay in Post-Anesthesia Care Unit (PACU)

    Total number of hours from the date of surgery to hospital discharge.

    Time frame: Up to 30 days after surgery.

  5. 30-Day Mortality

    All-cause mortality occurring within 30 days after surgery.

    Time frame: Up to 30 days after surgery.

07

Study locations

1 site
  • Andre Prato Schmidt
    Porto Alegre, Rio Grande do Sul 90035903, Brazil
08

References and documents

Publications

  • Schmidt AP, Silvello D, Filho CTB, Bergmann D, Ferreira LEC, Nolasco MF, Pires TD, Braga WC, Andrade CF. Effects of Neuraxial or General Anesthesia on the Incidence of Postoperative Pulmonary Complications in Patients Undergoing Peripheral Vascular Surgery: A Randomized Controlled Trial. J Cardiothorac Vasc Anesth. 2025 Mar;39(3):724-732. doi: 10.1053/j.jvca.2024.12.027. Epub 2024 Dec 21. PubMed 39779428 ↗
  • Schmidt AP, Marques AJ, Reinstein AR, Bevilacqua Filho CT, Carmona MJC, Auler JOC Jr, Felix EA, Andrade CF. Effects of protective mechanical ventilation during general anesthesia in patients undergoing peripheral vascular surgery: A randomized controlled trial. J Clin Anesth. 2020 May;61:109656. doi: 10.1016/j.jclinane.2019.109656. Epub 2019 Nov 26. No abstract available. PubMed 31784303 ↗
  • Li A, Dreksler H, Nagpal SK, Brandys T, Jetty P, Dubois L, Parsons Leigh J, Stelfox HT, McIsaac DI, Roberts DJ. Outcomes After Neuraxial or Regional Anaesthesia Instead of General Anaesthesia for Lower Limb Revascularisation Surgery: A Systematic Review and Meta-Analysis of Randomised and Non-Randomised Studies. Eur J Vasc Endovasc Surg. 2023 Mar;65(3):379-390. doi: 10.1016/j.ejvs.2022.10.046. Epub 2022 Nov 3. PubMed 36336286 ↗

Individual participant data

Plan to share: No — Plan to Share Individual Participant Data (IPD)? - No IPD Sharing Description: The individual participant data (IPD) collected during the study will not be made publicly available due to ethical considerations and patient confidentiality. Plan to Share IPD with Other Researchers? No Available Supporting Information: Not applicable - Time Frame and Access Criteria: Not applicable

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Nov 2027, 28 months later.

Of 395 non-industry interventional studies with no phase under Postoperative Complications, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's planned 28 months is above that.

Counting every sponsor, half of 399 studies reached it within 20 months; a quarter within 8 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
May 1, 2025
StartEst.
Jul 1, 2025
Primary completionEst.
Nov 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06953128
Collaborators
Grupo Hospitalar Conceição
Responsible party
Sponsor
First posted
May 1, 2025
Start date
Jul 1, 2025 (estimated)
Primary completion
Nov 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jun 26, 2025

Study contacts

Andre P Schmidt, MD, PhD
Contact
apschmidt@hcpa.edu.br
5551996412212
Sabrina Coelli, MD
Contact
sabrina.coelli@gmail.com
5551981481343
Andre P Schmidt, MD, PhD
principal investigator · Hospital de Clínicas de Porto Alegre (HCPA)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion